The pathway of isolated seminal vesicle invasion has a different impact on biochemical recurrence after radical prostatectomy and pelvic lymphadenectomy.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
06 2023
Historique:
received: 24 11 2022
revised: 20 01 2023
accepted: 20 03 2023
medline: 9 6 2023
pubmed: 5 5 2023
entrez: 4 5 2023
Statut: ppublish

Résumé

Prostate cancer with seminal vesicle invasion (SVI) has been considered an aggressive cancer. To evaluate the prognostic significance of different patterns of isolated SVI in patients undergoing radical prostatectomy (RP) and pelvic lymphadenectomy. We retrospectively analyzed all patients who underwent RP between 2007 and 2019. Inclusion criteria were localized prostate adenocarcinoma, SVI at RP, at least 24-months follow-up, and no adjuvant treatment. Patterns of SVI were following Ohori's classification: type 1: direct spread along the ejaculatory duct from inside; type 2: seminal vesicle invasion outside the prostate, through the capsule; type 3: the presence of cancer island(s) in the seminal vesicle with no continuity from the primary tumor (discontinuous metastases). Patients with type 3 SVI (isolated or in association) were included in the same group. Biochemical recurrence (BCR) was defined as any postoperative PSA ≥0.2 ng/ml. A logistic regression analysis was performed to assess predictors of BCR. Time to BCR was investigated using the Kaplan-Meier analysis with the log-rank test. Sixty-one out of 1,356 patients were included. Median age was 67(7.2) years. Median PSA was 9.4(8.92) ng/ml. Mean follow-up was 85.28 ± 45.27 months. BCR occurred in 28(45.9%) patients. Logistic regression showed that a positive surgical margin (OR 19.964, 95%CI:1.172-29.322, P = 0.038) was predictor of BCR. Kaplan-Meier analysis demonstrated that patients with pattern 3 had a significantly shorter time to BCR compared to other groups (log-rank, P = 0.016). The estimated time to BCR was 48.7 months in type 3, 60.9 months in pattern 1 + 2, 74.8, and 100.8 months in isolated patterns 1 and 2, respectively. In patients with negative surgical margins, pattern 3 confirmed a shorter time to BCR compared to other types of invasions, with an estimated time to BCR of 30.8 months. Patients with type 3 SVI demonstrated a shorter time to BCR compared to other patterns.

Identifiants

pubmed: 37142452
pii: S1078-1439(23)00095-9
doi: 10.1016/j.urolonc.2023.03.011
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

293.e9-293.e14

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflict of interest.

Auteurs

Andrea B Galosi (AB)

Urology Division, Azienda Ospedaliero-Universitaria delle Marche, School of Urology, Polytechnic University of the Marche Region, Ancona, Italy.

Giulio Milanese (G)

Urology Division, Azienda Ospedaliero-Universitaria delle Marche, School of Urology, Polytechnic University of the Marche Region, Ancona, Italy.

Lorenzo Montesi (L)

Urology Division, Azienda Ospedaliero-Universitaria delle Marche, School of Urology, Polytechnic University of the Marche Region, Ancona, Italy.

Alessia Cimadamore (A)

Section of Pathological Anatomy, Azienda Ospedaliero-Universitaria delle Marche, Marche Polytechnic University, Ancona, Italy.

Carmine Franzese (C)

Urology Division, Azienda Ospedaliero-Universitaria delle Marche, School of Urology, Polytechnic University of the Marche Region, Ancona, Italy.

Erika Palagonia (E)

Urology Division, Azienda Ospedaliero-Universitaria delle Marche, School of Urology, Polytechnic University of the Marche Region, Ancona, Italy.

Giuseppe Chiacchio (G)

Urology Division, Azienda Ospedaliero-Universitaria delle Marche, School of Urology, Polytechnic University of the Marche Region, Ancona, Italy.

Daniele Castellani (D)

Urology Division, Azienda Ospedaliero-Universitaria delle Marche, School of Urology, Polytechnic University of the Marche Region, Ancona, Italy. Electronic address: castellanidaniele@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH